Dana-Farber and the Broad are using social media to identify extraordinary responders and other outlier patients to study what makes them genetically unique.

The Asian cancer biotech firm will use ACT's genomic tools to research why some patients responded unusually well to its pan-HER inhibitor.

Absent mature data suggesting that Genentech's biomarker strategy would likely prove Avastin's efficacy in a subpopulation, ODAC members did not want to expose patients unnecessarily to a toxic agent for many years to come.

If Genentech produces data showing substantial benefit in a subset of patients, "a new science-based indication could be approved," an FDA official said. "Until that time, it is not appropriate for the drug to continue to be approved for the treatment of breast cancer when the totality of the available data does not support such an approval."

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.